Hairy Cell Leukemia - Etiopathogenesis, Diagnosis and Modern Therapeutic Approach

Overview

Journal Biochem Med (Zagreb)

Specialty Biochemistry

Date 2024 Jun 17

PMID 38882583

Authors

Katarzyna Mackowiak

Magdalena Jankowiak

Karolina Szewczyk-Golec

Iga Holynska-Iwan

Affiliations

Soon will be listed here.

Abstract

Hairy cell leukemia (HCL) represents 2% of all leukemia cases, with men aged above 55 years being the most affected. The most common symptoms of this type of leukemia include splenomegaly, monocytopenia, and neutropenia. In the basic blood count examination, leukopenia with monocytopenia and granulocytopenia, as well as aplastic anemia and/or thrombocytopenia occur. The mutation of β-rapidly accelerated fibrosarcoma () proto-oncogene, which can be found in nearly 100% of patients, is an important feature of HCL. Immunophenotypic analysis of the HCL cells reveals high expression of B-lineage antigens, including CD19, CD20, and CD22. Additionally, CD11c, CD25, CD103, and CD123 belong to specific markers of HCL. Lactate dehydrogenase activity and β-2-microglobulin concentration are also important in the patient's assessment. The differential diagnosis between HCL, hairy cell leukemia variant (HCL-V) and splenic marginal zone lymphoma (SMZL) is of first importance. Currently, the main treatment for HCL involves the use of purine analogues, excluding pregnant women, individuals with severe infections, and those with relapsing HCL.

References

Maral S, Albayrak M, Dagdas S, Yildiz A, Yildirim R, Oz M . Prognostic Value of Baseline Serum Lactate Dehydrogenase Level in Patients With Hairy Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2020; 20(9):e616-e621. DOI: 10.1016/j.clml.2020.04.005. View

Gaman A . Hairy cell leukemia--a rare type of leukemia. A retrospective study on 39 patients. Rom J Morphol Embryol. 2013; 54(3):575-9. View

Liu Q, Harris N, Epperla N, Andritsos L . Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant. Onco Targets Ther. 2021; 14:1797-1805. PMC: 7955867. DOI: 10.2147/OTT.S242247. View

Parry-Jones N, Joshi A, Forconi F, Dearden C . Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V). Br J Haematol. 2020; 191(5):730-737. DOI: 10.1111/bjh.17055. View

Kreitman R, Arons E . Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. Blood Rev. 2021; 51:100888. PMC: 8418384. DOI: 10.1016/j.blre.2021.100888. View

De Novellis D, Giudice V, Ciccone V, Erra P, De Vita A, Picone F . A Frail Hairy Cell Leukemia Patient Successfully Treated with Pegylated Interferon-α-2A. J Clin Med. 2023; 12(1). PMC: 9821323. DOI: 10.3390/jcm12010193. View

Tadros J, Davis A, Awoleye O, Vassiliou E . A case report of early diagnosis of asymptomatic hairy cell leukemia using flow cytometry. Front Immunol. 2023; 14:1207443. PMC: 10239883. DOI: 10.3389/fimmu.2023.1207443. View

Mendez-Hernandez A, Moturi K, Hanson V, Andritsos L . Hairy Cell Leukemia: Where Are We in 2023?. Curr Oncol Rep. 2023; 25(8):833-840. PMC: 10126561. DOI: 10.1007/s11912-023-01419-z. View

Roider T, Falini B, Dietrich S . Recent advances in understanding and managing hairy cell leukemia. F1000Res. 2018; 7. PMC: 5931274. DOI: 10.12688/f1000research.13265.1. View

10.

Maitre E, Cornet E, Troussard X . Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019; 94(12):1413-1422. DOI: 10.1002/ajh.25653. View

11.

Li D, Zhang Y, Xu H, Zhang X . The role of BRAF in the pathogenesis of thyroid carcinoma. Front Biosci (Landmark Ed). 2015; 20(7):1068-78. DOI: 10.2741/4359. View

12.

Grever M, Abdel-Wahab O, Andritsos L, Banerji V, Barrientos J, Blachly J . Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2016; 129(5):553-560. PMC: 5290982. DOI: 10.1182/blood-2016-01-689422. View

13.

Angelova E, Medeiros L, Wang W, Muzzafar T, Lu X, Khoury J . Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Mod Pathol. 2018; 31(11):1717-1732. DOI: 10.1038/s41379-018-0093-8. View

14.

Sherman M, Hanson C, Hoyer J . An assessment of the usefulness of immunohistochemical stains in the diagnosis of hairy cell leukemia. Am J Clin Pathol. 2011; 136(3):390-9. DOI: 10.1309/AJCP5GE1PSBMBZTW. View

15.

Maitre E, Cornet E, Salaun V, Kerneves P, Cheze S, Repesse Y . Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders. Cancers (Basel). 2022; 14(4). PMC: 8870214. DOI: 10.3390/cancers14041050. View

16.

Melenotte C, Mezouar S, Mege J, Gorvel J, Kroemer G, Raoult D . Bacterial infection and non-Hodgkin's lymphoma. Crit Rev Microbiol. 2020; 46(3):270-287. DOI: 10.1080/1040841X.2020.1760786. View

17.

Pula A, Robak T . Hairy cell leukemia: a brief update on current knowledge and treatment prospects. Curr Opin Oncol. 2021; 33(5):412-419. DOI: 10.1097/CCO.0000000000000771. View

18.

Hu Z, Sun Y, Wang W, Medeiros L, Kanagal-Shamanna R . Refractory hairy cell leukemia-variant. Am J Hematol. 2016; 92(12):1398-1399. DOI: 10.1002/ajh.24580. View

19.

Grever M, Blachly J, Andritsos L . Hairy cell leukemia: Update on molecular profiling and therapeutic advances. Blood Rev. 2014; 28(5):197-203. DOI: 10.1016/j.blre.2014.06.003. View

20.

Bohn J, Salcher S, Pircher A, Untergasser G, Wolf D . The Biology of Classic Hairy Cell Leukemia. Int J Mol Sci. 2021; 22(15). PMC: 8346068. DOI: 10.3390/ijms22157780. View